company background image
CERE

Cerevel Therapeutics Holdings NasdaqCM:CERE Stock Report

Last Price

US$28.37

Market Cap

US$4.4b

7D

-2.6%

1Y

-13.6%

Updated

01 Dec, 2022

Data

Company Financials +
CERE fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

CERE Stock Overview

Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases.

Cerevel Therapeutics Holdings, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Cerevel Therapeutics Holdings
Historical stock prices
Current Share PriceUS$28.37
52 Week HighUS$41.46
52 Week LowUS$19.86
Beta1.64
1 Month Change-3.24%
3 Month Change-3.96%
1 Year Change-13.59%
3 Year Changen/a
5 Year Changen/a
Change since IPO138.40%

Recent News & Updates

Cerevel overweight at Wells Fargo due to candidates with blockbuster potential

Sep 26

Recent updates

We're Not Very Worried About Cerevel Therapeutics Holdings' (NASDAQ:CERE) Cash Burn Rate

Jun 09
We're Not Very Worried About Cerevel Therapeutics Holdings' (NASDAQ:CERE) Cash Burn Rate

Is Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Popular Amongst Institutions?

Jan 29
Is Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Popular Amongst Institutions?

Shareholder Returns

CEREUS BiotechsUS Market
7D-2.6%2.7%1.4%
1Y-13.6%-10.3%-16.1%

Return vs Industry: CERE underperformed the US Biotechs industry which returned -10.2% over the past year.

Return vs Market: CERE exceeded the US Market which returned -14.8% over the past year.

Price Volatility

Is CERE's price volatile compared to industry and market?
CERE volatility
CERE Average Weekly Movement7.5%
Biotechs Industry Average Movement11.2%
Market Average Movement7.4%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market3.3%

Stable Share Price: CERE is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: CERE's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2018285Tony Coleshttps://www.cerevel.com

Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures in epilepsy or focal epilepsy, as well as in phase 1 trial to treat acute anxiety. The company’s products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson’s disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; CVL-936, a selective dopamine D3-preferring antagonist, which is in Phase I clinical trial for the treatment of substance use disorder; CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder; and CVL-047, selective PDE4 inhibitor for the treatment of major depressive disorder and substance use disorder.

Cerevel Therapeutics Holdings, Inc. Fundamentals Summary

How do Cerevel Therapeutics Holdings's earnings and revenue compare to its market cap?
CERE fundamental statistics
Market CapUS$4.43b
Earnings (TTM)-US$317.76m
Revenue (TTM)n/a

0.0x

P/S Ratio

-13.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CERE income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$317.76m
Earnings-US$317.76m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-2.03
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio66.0%

How did CERE perform over the long term?

See historical performance and comparison